The news correspondents obtained a quote from the research from University Medical Center, "AREAS COVERED: Sertindole's pharmacological profile, pharmacokinetics, neuophysiological properties, efficacy on positive, negative and cognitive symptoms and safety issues are covered in this article, based on a literature review from 1990 to 2012. EXPERT OPINION: Based on five double-blind, randomized, placebo-, haloperidol-or risperidone-controlled studies in patients with schizophrenia, sertindole shows a comparable efficacy with haloperidol and risperidone on positive symptoms, while the effect on negative symptoms seems to be superior. Sertindole is generally well tolerated, but is associated with a dose-related QTc interval prolongation (+22 ms). Risk factors for drug-induced arrhythmia, such as cardiac diseases, congenital long QT syndrome, prolongated QTc at baseline, etc. and drug interactions should be considered before prescribing sertindole. To minimize cardiovascular risk, regular ECG recording is required. Sertindole can be an important second-line option for the treatment of schizophrenia for patients intolerant to at least one other antipsychotic."
According to the news reporters, the research concluded: "Further comparison with other SGAs and investigations on subgroups (e.g., children, elderly, first-episode, treatment-refractory patients, etc.) are still needed for a precise understanding of the therapeutic benefits and its role in schizophrenia therapy."
For more information on this research see: Drug safety and efficacy evaluation of sertindole for schizophrenia. Expert Opinion On Drug Safety, 2012;11(6):1047-62.
Our news journalists report that additional information may be obtained by contacting E. Karamatskos, University Medical Center Hamburg-Eppendorf, Centre of Psychosocial Medicine, Dept. of Psychiatry and Psychotherapy, Martinistr 52, D-20246 Hamburg, Germany.
Keywords for this news article include: Antipsychotic, Europe, Hamburg, Germany, Psychiatry, Mental Health, Schizophrenia.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.